Literature DB >> 18622269

Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation.

Xian-Liang Li1, Séverine Ménoret, Brigitte Le Mauff, Mathieu Angin, Ignacio Anegon.   

Abstract

Although clinical trials using anti-CD40L mAb have been halted, blockade of CD40-CD40L interactions has given promising results in rodent and nonhuman primate models. Recently, new insights into the consequences of blocking CD40-CD40L interactions have led to the possibility of overcoming the thromboembolic complications previously associated with this strategy and may pave the way for successful tolerance induction. This mini review will address the issues relating to CD40-CD40L blockade in allotransplantation.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18622269     DOI： 10.1097/TP.0b013e31817c4b97

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


  11 in total

Review 1.  Regulatory T-cell therapy in transplantation: moving to the clinic.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

2.  CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation.

Authors:  Katayoun Ayasoufi; Ran Fan; Robert L Fairchild; Anna Valujskikh
Journal:  J Immunol       Date:  2016-02-24       Impact factor: 5.422

Review 3.  Immune Tolerance for Autoimmune Disease and Cell Transplantation.

Authors:  Xunrong Luo; Stephen D Miller; Lonnie D Shea
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

4.  MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection.

Authors:  Elodie Picarda; Séverine Bézie; Vanessa Venturi; Klara Echasserieau; Emmanuel Mérieau; Aurélie Delhumeau; Karine Renaudin; Sophie Brouard; Karine Bernardeau; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

5.  GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.

Authors:  Weston P Miller; Swetha Srinivasan; Angela Panoskaltsis-Mortari; Karnail Singh; Sharon Sen; Kelly Hamby; Taylor Deane; Linda Stempora; Jonathan Beus; Alexa Turner; Caleb Wheeler; Daniel C Anderson; Prachi Sharma; Anapatricia Garcia; Elizabeth Strobert; Eric Elder; Ian Crocker; Timothy Crenshaw; M Cecilia T Penedo; Thea Ward; Mingqing Song; John Horan; Christian P Larsen; Bruce R Blazar; Leslie S Kean
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

Review 6.  Islet cell xenotransplantation: a serious look toward the clinic.

Authors:  Kannan P Samy; Benjamin M Martin; Nicole A Turgeon; Allan D Kirk
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

Review 7.  Costimulation blockade: current perspectives and implications for therapy.

Authors:  Gillian Kinnear; Nick D Jones; Kathryn J Wood
Journal:  Transplantation       Date:  2013-02-27       Impact factor: 4.939

8.  Alloreactive Regulatory T Cells Allow the Generation of Mixed Chimerism and Transplant Tolerance.

Authors:  Paulina Ruiz; Paula Maldonado; Yessia Hidalgo; Daniela Sauma; Mario Rosemblatt; Maria Rosa Bono
Journal:  Front Immunol       Date:  2015-11-23       Impact factor: 7.561

9.  Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys.

Authors:  Lijun Song; Anlun Ma; Hao Dun; Yanxin Hu; Lin Zeng; Jieying Bai; Guangzhou Zhang; Fumitaka Kinugasa; Yuji Sudo; Yasuhiro Miyao; Kazumichi Okimura; Toru Miura; Pierre Daloze; Huifang Chen
Journal:  Transplantation       Date:  2014-08-15       Impact factor: 4.939

10.  Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance.

Authors:  Sarah Sharon Gabriel; Nina Bon; Jin Chen; Thomas Wekerle; Andrew Bushell; Thomas Fehr; Pietro Ernesto Cippà
Journal:  Front Immunol       Date:  2016-03-01       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.